Dallas, TX -- (SBWIRE) -- 11/29/2013 --
The report titled "Global Multiple Sclerosis Market: Trends &
Opportunities (2013-18)" provide an insight into the market dynamics and
various trends and opportunities associated with the global multiple
sclerosis market. The report analyzes the various causes and symptoms
related to the prevalence of MS in patients. Further, the report
analyzes the global market sizing and growth of multiple sclerosis in
terms of revenue, number of patients and sales of effective drugs. Also,
the domestic market of United States which is the largest contributor
to the global multiple sclerosis market has been assessed. The report
concludes with a brief discussion of major factors driving the global
multiple sclerosis market and profiles major players like Teva, Biogen
Idec, Merck KGaA, Bayer and Novartis.
The global Multiple Sclerosis market is undergoing drastic change since
the last few years. The rising diagnosis and treatment rate coupled with
growing investment in research and development has played a key role in
the determining the growth dynamics of the global Multiple Sclerosis
(MS) market.
Currently, MS is known to affect an estimated 2.5 million people around
the world with around 5000 new cases emerging each year. Since there is
no particular cure or treatment for multiple sclerosis, the market is
currently dominated by few drugs and medication like Copaxone, Avonex,
Betaseron and Extavia which delay or reduce the progression of multiple
sclerosis in individuals.
Until the last year, MS market was led by self injectables drugs such as
Capaxone and Avonex that caused side effects like swelling, anxiety,
redness and difficult breathing. To address these shortcomings and side
effects, pharmaceutical companies developed oral drugs that are
considered safe and effective. With the beginning of 2013, oral drugs
such as Gilenya and Aubagio witnessed rapid demand due to their higher
efficacy and better results. In addition, there are many drugs down the
pipeline that would change the dynamics and growth of the multiple
sclerosis market in future. For instance, Teva hopes its Copaxone
successor, laquinimod, may help it preserve some market share when
Copaxone loses patent protection.
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia
